SCHEMBL375897

SCHEMBL375897

COc1cc(C(=O)O)c([N+](=O)[O-])cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.59
LMNA P02545 3/20 0.58
POLB P06746 2/20 0.58
HTT P42858 1/20 0.58
CYP3A4 P08684 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NPC1 O15118 1/20 0.56
KDM4E B2RXH2 2/20 0.54
MAPT P10636 3/20 0.53
MEN1 O00255 1/20 0.53
GAA P10253 1/20 0.53
KMT2A Q03164 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
ALDH1A1 P00352 2/20 0.53
ALOX15 P16050 1/20 0.53
PRKDC P78527 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31549975 1.00 PKM (0.59) PKMLMNAPOLBHTTCYP3A4
Methyl Alcohol SCHEMBL27781670 0.98 PKM (0.58) PKMLMNAPOLBHTTCYP3A4
SCHEMBL3698713 0.92 PKM (0.52) PKMLMNAPOLBHTTCYP3A4
Methacrylic Acid SCHEMBL28701003 0.92 PKM (0.52) PKMLMNAPOLBHTTCYP3A4
SCHEMBL28454415 0.91 PKM (0.58) PKMLMNAPOLBHTTCYP3A4
SCHEMBL2903458 0.91 PKM (0.58) PKMLMNAPOLBHTTCYP3A4
SCHEMBL23734428 0.91 PKM (0.51) PKMLMNAPOLBHTTCYP3A4
SCHEMBL3698716 0.91 PKM (0.51) PKMLMNAPOLBHTTCYP3A4
SCHEMBL2610746 0.91 POLB (0.54) PKMLMNAPOLBHTTCYP3A4
SCHEMBL20630551 0.89 POLB (0.56) PKMLMNAPOLBHTTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 576 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-118420595-A STING agonist ST-76 and synthetic method and application thereof 河南牧业经济学院 2024-08-02 CN claimed
CN-113200861-B Preparation method and application of 6-nitro veratric acid 山东科加工业技术研究院有限公司 2023-05-09 CN claimed
CN-110590683-B Preparation method of intermediate of targeting drug AZD3759 山东四环药业股份有限公司 2022-08-19 CN claimed
CN-114656435-A Rockmilan alcohol hydroxyl derivative, preparation method and application thereof 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2022-06-24 CN claimed
CN-114031834-A High-temperature-resistant, damp-proof, anti-corrosion and anti-aging PE film and preparation method thereof 江阴市江泰高分子新材料有限公司 2022-02-11 CN claimed
CN-112171831-B Wood protective agent and preparation and use methods thereof 海南博展实业有限公司 2021-09-28 CN claimed
CN-113200861-A Novel preparation method and application of 6-nitroveratric acid 山东科加工业技术研究院有限公司 2021-08-03 CN claimed
CN-112812016-A Method for preparing 6-nitro veratric acid from veratric acid by using microchannel reactor 山东天铭医药科技有限公司 2021-05-18 CN claimed
US-20050159385-A1 JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection SOUTH FLORIDA, UNIVERSITY OF 2005-07-21 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
EP-1310510-A2 Topologically segregated, encoded solid phase libraries SELECTIDE CORPORATION (US) 2003-05-14 EP claimed
EP-0705279-B1 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORP (US) 2003-02-19 EP claimed
US-6090912-A MULTIPLICITY OF SEPARATE SOLID SUPPORTS WITH SURFACE HAVING SUCEPTIBLE LINKER TO SINGLE SPECIES OF TEST COMPOUND AND WITH INTERIOR HAVING ATTACHED NON-CLEAVABLE CODING MOLECULE; FOR SCREENING LIGANDS OR ACCEPTORS SELECTIDE CORPORATION (US) 2000-07-18 US claimed
EP-0705279-A4 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORP (US) 1999-03-24 EP claimed
US-5840485-A SYNTHETIC TEST COMPOUNDS ATTACHED TO SEPARATE PHASE SYNTHESIS SUPPORTS THAT ALSO CONTAIN CODING MOLECULES THAT ENCODE THE STRUCTURE OF THE SYNTHETIC TEST COMPOUND SELECTIDE CORPORATION (US) 1998-11-24 US claimed
US-5547839-A CONTACTING POLYNUCLEOTIDES WITH SURFACE OF SOLID SUBSTRATE, HYBRIDIZING USING NUCLEIC ACID POLYMERASE AND LABELED NUCLEOTIDE AFFYMAX TECHNOLOGIES N.V. (AN) 1996-08-20 US claimed
EP-0705279-A1 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORPORATION (US) 1996-04-10 EP claimed
WO-1994028028-A1 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORPORATION (US) 1994-12-08 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 PKM 3579/4885LMNA 2024/4885POLB 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.